{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-006489","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2023-01-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.660858+00:00","generated_at":"2026-06-20T16:23:25.148311+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BioMarin estimates FY2022 total revenue of $2.09B, VOXZOGO sales $169M","bullets":["Preliminary unaudited total revenue for FY2022 estimated at $2.09 billion.","VOXZOGO contributed approximately $169 million in revenue for FY2022.","Revenue figures are preliminary and subject to completion of quarterly closing procedures.","Full FY2022 results expected to be reported in February 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-006489","json":"https://secwatch.observer/filing/0001193125-23-006489.json","markdown":"https://secwatch.observer/filing/0001193125-23-006489.md","text":"https://secwatch.observer/filing/0001193125-23-006489.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000119312523006489/0001193125-23-006489-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000119312523006489/d405652d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T16:23:25.148311+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"50b5f07f7011c514e8fcfc2da6ccebb824ac521a","claim":"BIOMARIN PHARMACEUTICAL INC reported the year ended December 31, 2022 results: revenue approximately $2.09 billion in total revenues (unaudited).","evidence_excerpt":"based on preliminary results the Company estimates that it generated approximately $2.09 billion in total revenues (unaudited) for the year ended December 31, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1048477/000119312523006489/0001193125-23-006489-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"approximately $2.09 billion in total revenues (unaudited)"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}